Successful Treatment of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Complicated by Severe Autoimmune Neutropenia With Rituximab and Bendamustine

A 73-year-old woman was diagnosed with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) with general fatigue and severe neutropenia. Although rituximab monotherapy was initiated, the neutrophil counts decreased within one week after rituximab administration. Subsequently, a combination of rituximab and bendamustine was initiated, and then her neutrophil counts became consistently within the normal range. The LPL/WM kept complete remission for two years. LPL/WM complicated with severe autoimmune neutropenia is rare. Rituximab and bendamustine brought strong lymphocyte depletion, leading to amelioration of autoimmune neutropenia. In this case, rituximab and bendamustine may have been active in patients with LPL/WM complicated with autoimmune disorders.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-09-28
DOI
https://doi.org/10.7759/cureus.93392
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Successful Treatment of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Complicated by Severe Autoimmune Neutropenia With Rituximab and Bendamustine

Taro Edahiro, Tatsuo Ichinohe, Hiroshi Ureshino, S. Nakatani et al.
Cureus
Chronic Lymphocytic Leukemia Research
article

Successful Treatment of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Complicated by Severe Autoimmune Neutropenia With Rituximab and Bendamustine

Taro Edahiro, Tatsuo Ichinohe, Hiroshi Ureshino, S. Nakatani, Tetsumi Yoshida
article en

Abstract

A 73-year-old woman was diagnosed with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) with general fatigue and severe neutropenia. Although rituximab monotherapy was initiated, the neutrophil counts decreased within one week after rituximab administration. Subsequently, a combination of rituximab and bendamustine was initiated, and then her neutrophil counts became consistently within the normal range. The LPL/WM kept complete remission for two years. LPL/WM complicated with severe autoimmune neutropenia is rare. Rituximab and bendamustine brought strong lymphocyte depletion, leading to amelioration of autoimmune neutropenia. In this case, rituximab and bendamustine may have been active in patients with LPL/WM complicated with autoimmune disorders.

CureusVol. 17(9)
Hiroshima University (JP), Saga University (JP), Hiroshima University Hospital (JP)
Openalex Percentile: Top 64%
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Successful Treatment of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Complicated by Severe Autoimmune Neutropenia With Rituximab and Bendamustine — Taro Edahiro, Tatsuo Ichinohe, et al. · Cureus (2025) | TGRS Research Map | TGRS